12 May 2020

Questionnaire to Sanofi Pasteur on COVID-19 Vaccine

Thank you for the constructive discussion held on 11 May on Sanofi Pasteur plans for the development, production and introduction of a vaccine for prophylaxis against COVID-19. As discussed, we would be grateful if you could reply to the following questions by Tuesday 19 May close of business.

Insofar as the information provided by you contains business secrets, your information will obviously be kept confidential (see Article 339 TFEU).

Our answers refer throughout to the Baculovirus recombinant protein vaccine.

Vaccine in Development
Production Capacities
Agreements for the Production of the Vaccine

Filling and further Steps for the Finalisation of the Production
Marketing and Distribution

Administration of the vaccine
Cooperation Agreements

Overall Time-frame

Main Risks for the Successful Development and Production

Agreements with Government and International Organisations
Liability
Regulatory Flexibility